Lumos Pharma (LUMO) Q2 2024 earnings summary

Executive summary

• Advanced plans for a Phase 3 placebo-controlled trial of LUM-201 in moderate pediatric growth hormone deficiency, with initiation expected in Q2 2025 following positive FDA feedback and successful Phase 2 results.

• Engaged Piper Sandler to explore strategic opportunities, including financings, alliances, or a possible sale, to maximize shareholder value and advance the LUM-201 platform.

• Presented new data from the OraGrowtH212 trial at major endocrinology conferences, highlighting LUM-201's efficacy, unique mechanism, and durable effect over 24 months.

• The company reported a net loss of $7.6 million for Q2 2024, with no commercial product sales to date.

• Substantial doubt exists about the company's ability to continue as a going concern beyond Q1 2025 without additional financing.

Financial highlights

• Ended Q2 2024 with $16.8 million in cash, cash equivalents, and short-term investments, down from $36 million at year-end 2023.

• Net loss for Q2 2024 was $7.6 million, improved from $8.9 million in Q2 2023.

• Research and development expenses were $4.6 million, down $1.4 million year-over-year, mainly due to lower contract manufacturing and personnel costs.

• General and administrative expenses were $3.7 million, a $0.5 million decrease from the prior year.

• Q2 2024 revenue was $0.5 million, down 7% year-over-year, due to lower ERVEBO® royalty income.

Outlook and guidance

• Phase 3 trial initiation is targeted for Q2 2025, subject to FDA approval, placebo manufacturing, and successful financing.

• Cash resources are expected to fund operations into Q1 2025; an estimated $85–100 million is needed to fund operations and the Phase 3 trial through Q4 2026.

• Management is evaluating all strategic opportunities and may delay or reduce R&D activities if funding is not secured.

• Targeting 15–18 months for enrollment of 150 patients across 80+ global sites, with data expected late 2026 or 2027.